Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBα for specific inhibition of nuclear factor-κB activity

Neoplasia

Volumn 12, Issue 10, 2010, Pages 766-777

  Zhou, Hong ^a   Liu, Yuying ^a   Cheung, Lawrence H ^a   Kim, Sehoon ^a   Zhang, Weihe ^a   Mohamedali, Khalid A ^a   Anand, Preetha ^a   Hittelman, Walter N ^a   Aggarwal, Bharat B ^a   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; I KAPPA B ALPHA SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; RADIOSENSITIVITY; TARGET CELL; TRANSCRIPTION TERMINATION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 77957792301     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10214     Document Type: Article

References (50)

1. Ivanov VN, Bhoumik A, and Ronai Z (2003). Death receptors and melanoma resistance to apoptosis. Oncogene 22, 3152-3161.
2. Nyormoi O and Bar-Eli M (2003). Transcriptional regulation of metastasisrelated genes in human melanoma. Clin Exp Metastasis 20, 251-263.
3. Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, and Zamora A (2007). The transcription factor nuclear factor-κB and cancer. Clin Oncol (R Coll Radiol) 19, 154-161.
4. Okamoto T, Sanda T, and Asamitsu K (2007). NF-κB signaling and carcinogenesis. Curr Pharm Des 13, 447-462.
5. Giacomini P, Ng AK, Kantor RR, Natali PG, and Ferrone S (1983). Double determinant immunoassay to measure a human high-molecular-weight melanomaassociated antigen. Cancer Res 43, 3586-3590.
6. Rentsch M, Cerny T, Geiger L, Gerber H, Brunner KW, Rosler H, and Nachbur B (1989). Radioimmunoscintigraphy with a 99mTc-labeled F(ab′)2 fragment of a monoclonal antibody (HMW-MAA 225.28S) in 71 patients with malignant melanoma. Schweiz Med Wochenschr 119, 1382-1385.
7. Wilson BS, Ruberto G, and Ferrone S (1983). Immunochemical characterization of a human high molecular weight-melanoma associated antigen identified with monoclonal antibodies. Cancer Immunol Immunother 14, 196-201.
8. Kirkwood JM, Neumann RD, Zoghbi SS, Ernstoff MS, Cornelius EA, Shaw C, Ziyadeh T, Fine JA, and Unger MW (1987). Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol 5, 1247-1255.
9. Briassouli P, Chan F, Savage K, Reis-Filho JS, and Linardopoulos S (2007). Aurora-A regulation of nuclear factor-κB signaling by phosphorylation of IκBα. Cancer Res 67, 1689-1695.
10. Calzado MA, Bacher S, and Schmitz ML (2007). NF-κB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 14, 367-376.
11. Melisi D and Chiao PJ (2007). NF-κB as a target for cancer therapy. Expert Opin Ther Targets 11, 133-144.
12. Morotti A, Cilloni D, Pautasso M, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, et al. (2006). NF-κB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. Am J Hematol 81, 938-945.
13. Pacifico F and Leonardi A (2006). NF-κB in solid tumors. Biochem Pharmacol 72, 1142-1152.
14. Morgan AC Jr, Galloway DR, and Reisfeld RA (1981). Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1, 27-36.
15. Schulz G, Bumol TF, and Reisfeld RA (1983). Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 80, 5407-5411.
16. Schulz G, Staffileno LK, Reisfeld RA, and Dennert G (1985). Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells. J Exp Med 161, 1315-1325.
17. Liu Y, Zhang W, Cheung LH, Niu T, Wu Q, Li C, Van Pelt CS, and Rosenblum MG (2006). The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia 8, 384-393.
18. Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, Meyn RE Jr, and Rosenblum MG (2006). Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity. Neoplasia 8, 125-135.
19. Reichelt P, Schwarz C, and Donzeau M (2006). Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif 46, 483-488.
20. Holmes K, Lantz LM, Fowlkes BJ, Schmid I, and Giorgi JV (2001). Preparation of cells and reagents for flow cytometry. Curr Protoc Immunol Chapter 5,Unit 5.3.
21. Rosenblum MG, Cheung L, Murray JL, and Bartholomew R (1991). Antibodymediated delivery of tumor necrosis factor (TNF-α): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun 3, 21-27.
22. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, and Rosenblum MG (2007). The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 6, 460-470.
23. Liu Y, Cheung LH, Hittelman WN, and Rosenblum MG (2003). Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2, 1341-1350.
24. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, and Rabson AB (2002).Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 52, 183-200.
25. Aggarwal S, Takada Y, Mhashilkar AM, Sieger K, Chada S, and Aggarwal BB (2004). Melanoma differentiation-associated gene-7/IL-24 gene enhances NF-κB activation and suppresses apoptosis induced by TNF. J Immunol 173, 4368-4376.
26. Darnay BG, Ni J, Moore PA, and Aggarwal BB (1999). Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274, 7724-7731.
27. Munshi A, Hobbs M, and Meyn RE (2005). Clonogenic cell survival assay. Methods Mol Med 110, 21-28.
28. Aida Y and Pabst MJ (1990). Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 132, 191-195.
29. Kumar A, Takada Y, Boriek AM, and Aggarwal BB (2004). Nuclear factor-κB: its role in health and disease. J Mol Med 82, 434-448.
30. Yan Liu X, Robinson D, Veach RA, Liu D, Timmons S, Collins RD, and Hawiger J (2000). Peptide-directed suppression of a pro-inflammatory cytokine response. J Biol Chem 275, 16774-16778.
31. Lee JH, Koo TH, Hwang BY, and Lee JJ (2002). Kaurane diterpene, kamebakaurin, inhibits NF-κB by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-κB target genes. J Biol Chem 277, 18411-18420.
32. Pande V, Sharma RK, Inoue J, Otsuka M, and Ramos MJ (2003). A molecular modeling study of inhibitors of nuclear factor κ-B (p50)-DNA binding. J Comput Aided Mol Des 17, 825-836.
33. Watanabe M, Ohsugi T, Shoda M, Ishida T, Aizawa S, Maruyama-Nagai M, Utsunomiya A, Koga S, Yamada Y, Kamihira S, et al. (2005). Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106, 2462-2471.
34. Thomas RK, Sos ML, Zander T, Mani O, Popov A, Berenbrinker D, Smola-Hess S, Schultze JL, and Wolf J (2005). Inhibition of nuclear translocation of nuclear factor-κB despite lack of functional IκBα protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies. Clin Cancer Res 11, 8186-8194.
35. Kim BH, Lee KH, Chung EY, Chang YS, Lee H, Lee CK, Min KR, and Kim Y (2006). Inhibitory effect of chroman carboxamide on interleukin-6 expression in response to lipopolysaccharide by preventing nuclear factor-κBactivation inmacrophages. Eur J Pharmacol 543, 158-165.
36. Hwang DM, Kundu JK, Shin JW, Lee JC, Lee HJ, and Surh YJ (2007). Cis-9, trans-11-Conjugated linoleic acid down-regulates phorbol ester-induced NF-κB activation and subsequent COX-2 expression in hairless mouse skin by targeting IκB kinase and PI3K-Akt. Carcinogenesis 28, 363-371.
37. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, and Lee JJ (2006). Inhibition of NF-κB activation through targeting IκB kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 72, 1311-1321.
38. Cho ML, Ju JH, Kim KW, Moon YM, Lee SY, Min SY, Cho YG, Kim HS, Park KS, Yoon CH, et al. (2007). Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-κB. Immunol Lett 108, 88-96.
39. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Rmaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, et al. (2007). Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin Cancer Res 13, 3423-3430.
40. Zambre AP, Kulkarni VM, Padhye S, Sandur SK, and Aggarwal BB (2006). Novel curcumin analogs targeting TNF-induced NF-κB activation and proliferation in human leukemic KBM-5 cells. Bioorg Med Chem 14, 7196-7204.
41. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL, and Slaga TJ (2003). 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NFκB cell survival signaling pathway: potential for prostate cancer management. Neoplasia 5, 255-266.
42. Berman KS, Verma UN, Harburg G, Minna JD, Cobb MH, and Gaynor RB (2002). Sulindac enhances tumor necrosis factor-α-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-κB. Clin Cancer Res 8, 354-360.
43. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, and Ghosh S (2000). Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 289, 1550-1554.
44. Kantor RR, Ng AK, Giacomini P, and Ferrone S (1982). Analysis of the NIHworkshop monoclonal antibodies to human melanoma antigens. Hybridoma 1, 473-482.
45. Macey DJ, DeNardo SJ, DeNardo GL, Goodnight JK, and Unger MW (1988). Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. Am J Physiol Imaging 3, 1-6.
46. Rosenblum MG, Levin B, Roh M, Hohn D, McCabe R, Thompson L, Cheung L, and Murray JL (1994). Clinical pharmacology and tissue disposition studies of 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88. Cancer Immunol Immunother 39, 397-400.
47. Melnikova VO and Bar-Eli M (2009). Inflammation and melanoma metastasis. Pigment Cell Melanoma Res 22, 257-267.
48. Munshi A, Kurland JF, Nishikawa T, Chiao PJ, Andreeff M, and Meyn RE (2004). Inhibition of constitutively activated nuclear factor-κB radiosensitizes human melanoma cells. Mol Cancer Ther 3, 985-992.
49. Melnikova VO and Bar-Eli M (2008). Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 7, 997-1003.
50. Zigler M, Villares GJ, Lev DC, Melnikova VO, and Bar-Eli M (2008). Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol 9, 307-311.